Congenital Bile Acid Synthesis Defect 5 (CBAS5) — Comprehensive Research Report

1. Disease Information

Overview. Congenital Bile Acid Synthesis Defect 5 (CBAS5) is an ultra-rare autosomal recessive inborn error of peroxisomal metabolism caused by biallelic loss-of-function variants in ABCD3 (also known as PXMP1 / PMP70), which encodes a peroxisomal membrane ATP-binding cassette (ABC) half-transporter. ABCD3 imports the CoA-thioesters of the C27 bile acid intermediates di- and trihydroxycholestanoic acid (DHCA-CoA, THCA-CoA) — and branched-chain fatty acyl-CoAs — into the peroxisomal matrix, where peroxisomal β-oxidation shortens the C27 side chain to yield mature C24 primary bile acids (chenodeoxycholic acid, CA and CDCA). Loss of ABCD3 blocks this peroxisomal import step, causing failure to generate mature bile acids and pathological accumulation of hepatotoxic C27 bile acid intermediates, which presents clinically as progressive infantile cholestatic/fibrotic liver disease [Ferdinandusse et al., Hum Mol Genet 2015, PMID:25326392].

CBAS5 is the fifth entity in the "congenital bile acid synthesis defect" (CBAS1–5) nosological series, which groups genetically distinct single-gene defects along the classic (neutral) and alternative (acidic/peroxisomal) bile acid synthesis pathways by shared clinical phenotype (neonatal/infantile cholestasis with malabsorption) rather than by shared mechanism:

Key identifiers: - OMIM: #616278 (phenotype), 170995 (gene, ABCD3) - MONDO: MONDO:0014564 - Gene: ABCD3, HGNC:67, chromosome 1p21.3 - Orphanet: listed among congenital bile acid synthesis defects (ABCD3-related peroxisomal bile acid synthesis defect); note Orphanet/GeneReviews coverage of this specific ultra-rare entity is sparse given only one published family - MedGen*: linked concept for "Congenital bile acid synthesis defect 5"

Synonyms/alternative names: Bile acid synthesis defect, congenital, 5; PMP70 deficiency; ABCD3 deficiency; peroxisomal bile acid transporter deficiency; "novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3" (as titled in the founding report).

Evidence basis: The disease-defining information is derived almost entirely from a single published family (aggregated case-level clinical/biochemical/genetic data from one affected proband, supplemented by a corroborating Abcd3-knockout mouse model) rather than an aggregated disease-level registry or large cohort — a point OMIM itself flags: "only one family has been described in the literature and phenotypic association is not confirmed" [OMIM #616278; PMID:25326392].

2. Etiology

Disease causal factor: Purely monogenic/genetic. Biallelic (homozygous, in the only reported case — consistent with consanguinity) loss-of-function variants in ABCD3 abolish or severely impair the peroxisomal import of C27 bile acid intermediate–CoA esters, blocking peroxisomal β-oxidation shortening of the bile acid side chain.

Genetic risk factors: - Causal variant: The index patient (girl, born to consanguineous Turkish parents) carried a homozygous 1758-bp genomic deletion predicted to produce a truncated ABCD3 protein lacking its C-terminal 24 amino acids (p.Tyr635AsnfsTer1/p.Y635Nfs1), removing part of the second nucleotide-binding domain required for ATPase-driven transport [PMID:25326392]. - Consanguinity* was present in the only reported family, consistent with autosomal recessive transmission and a rare founder/private allele rather than a population-frequent variant. - No modifier genes or susceptibility loci have been reported given the extreme rarity (n=1 family).

Protective factors: None reported; no protective alleles or environmental protective factors are described for this ultra-rare condition.

Gene-environment interactions: None established. As a purely biosynthetic enzymatic/transport block, the phenotype is not known to be modulated by diet, toxin exposure, or infection, though — by analogy to other bile acid synthesis defects — cholestatic decompensation could plausibly be provoked by intercurrent illness or fasting (inferred from general bile acid synthesis defect biology, not demonstrated specifically for CBAS5).

3. Phenotypes

Because only one patient has been reported in detail, phenotype frequencies (e.g., "80% of patients") cannot be established; the description below is a single well-characterized case, corroborated mechanistically by mouse knockout hepatic pathology.

Onset: Infantile/early childhood — the index patient presented at 1.5 years of age, later than the neonatal-onset typical of CBAS1/CBAS2, though the underlying biochemical defect is congenital.

Severity/progression: Progressive — hepatosplenomegaly and biochemical derangement at presentation evolved to overt hepatic fibrosis, pancytopenia, coagulopathy/bleeding, and portal hypertension, culminating in liver transplantation at age 4 years; the patient reportedly died shortly after transplantation [PMID:25326392 as summarized in search-derived sources — verify primary text before final KB citation].

Quality of life impact: Not formally studied (EQ-5D/SF-36 data unavailable for a single pediatric case), but the natural history described (progression to transplant-requiring liver failure) implies severe impact on growth, nutrition (fat-malabsorption from bile acid deficiency), and survival absent intervention.

4. Genetic/Molecular Information

Causal gene: ABCD3 (ATP Binding Cassette Subfamily D Member 3; formerly PXMP1; protein alias PMP70). HGNC:67; OMIM *170995; chromosome 1p21.3; 659-amino-acid protein, 95% identical to rat ortholog.

Gene product/function: ABCD3 is a peroxisomal membrane half-ABC-transporter of the ALDP (ABCD) subfamily (which also includes ABCD1/ALDP, mutated in X-linked adrenoleukodystrophy, and ABCD2/ALDRP). Peroxisomal ABCD transporters function as homodimers or heterodimers and use ATP hydrolysis (via conserved Walker A/B nucleotide-binding-fold motifs in the C-terminal hydrophilic domain) to translocate CoA-thioesters of fatty acids and bile acid intermediates across the peroxisomal membrane. ABCD3 is the most abundant peroxisomal ABC transporter and has the broadest substrate range among the three (ABCD1–3), transporting branched-chain fatty acyl-CoAs, very-long-chain fatty acyl-CoAs, dicarboxylic fatty acyl-CoAs, and the C27 bile acid precursor-CoAs (DHCA-CoA, THCA-CoA) essential for bile acid synthesis.

Pathogenic variant identified: - Homozygous ~1758 bp genomic deletion → frameshift/truncation, p.Y635Nfs1, removing the C-terminal 24 residues (part of the second nucleotide-binding domain) [PMID:25326392]. - Variant classification: Pathogenic (functionally validated by immunoblot loss of protein and complementation/fibroblast studies in the founding paper, and independently corroborated by the Abcd3−/− mouse phenocopy). - Origin: Germline, biallelic (homozygous due to consanguinity). - Functional consequence: Loss of function (truncating variant predicted to destabilize/eliminate the transporter's nucleotide-binding domain, abolishing ATP-dependent transport activity). - Population frequency*: Not observed as a recurrent/founder allele; given a single reported family, allele frequency in gnomAD/1000 Genomes/TOPMed for this specific variant is expected to be absent or private (not independently verified against gnomAD in this session — recommend direct gnomAD lookup before KB citation).

Modifier genes: None established.

Epigenetic information: None reported for this disorder specifically.

Chromosomal abnormalities: None reported (variant is a small indel, not a large structural/chromosomal lesion detectable by karyotype/CMA).

Allelic disorders: ABCD3 variants have also been implicated more broadly in a mild/attenuated peroxisomal biogenesis-disorder-like or "Zellweger spectrum disorder"-adjacent liver phenotype in later literature discussions, though the canonical, OMIM-cataloged CBAS5 entry remains anchored to the single Ferdinandusse et al. family; this is a genuine unsettled lump/split question rather than a well-replicated distinct allelic series, and should be flagged as such rather than asserted definitively.

5. Environmental Information

No environmental, lifestyle, or infectious contributory factors have been reported for CBAS5. As with other congenital bile acid synthesis defects, disease expression is driven entirely by the germline enzymatic/transport block; there is no described toxin, occupational exposure, or dietary trigger. (By analogy with general bile acid synthesis defect biology, fat-soluble vitamin status and dietary fat content likely modulate the severity of secondary malabsorptive complications, but this has not been specifically documented for CBAS5.)

6. Mechanism / Pathophysiology

Causal chain (numbered, from initiating lesion to clinical manifestation)

1. Biallelic loss-of-function ABCD3 variant (e.g., the p.Y635Nfs1 truncation) leads to* loss/near-loss of functional peroxisomal ABCD3 transporter protein at the peroxisomal membrane [demonstrated, PMID:25326392].
2. Loss of ABCD3 results in failure of ATP-dependent import of the CoA-thioesters of the C27 bile acid intermediates DHCA-CoA and THCA-CoA (and of branched-chain fatty acyl-CoAs) into the peroxisomal matrix [demonstrated in patient fibroblasts and confirmed in Abcd3−/− mice].
3. Failure of peroxisomal import blocks the terminal peroxisomal β-oxidation step of bile acid synthesis — normally carried out by AMACR (racemization), ACOX2 (oxidation), HSD17B4/D-bifunctional enzyme (hydration/dehydrogenation), and SCPx (thiolytic chain-shortening cleavage of a propionyl-CoA unit) — that converts DHCA-CoA/THCA-CoA into the mature C24 bile acid-CoAs chenodeoxycholyl-CoA and cholyl-CoA [pathway established by prior biochemical literature; the block at the transport step is inferred from substrate accumulation, not directly visualized].
4. This block causes (a) deficient synthesis of mature primary bile acids (CA, CDCA) and (b) pathological accumulation of unmetabolized C27 bile acid intermediates (DHCA, THCA) and their upstream precursors in liver, plasma, and bile [demonstrated biochemically in the patient and in Abcd3−/− mouse tissues].
5. Deficient mature bile acid output leads to impaired bile flow/reduced bile acid-dependent bile secretion, contributing to cholestasis, and to intestinal malabsorption of dietary fat and fat-soluble vitamins (inferred by analogy with other CBAS entries; not separately quantified in the single reported case).
6. Accumulated C27 bile acid intermediates are hepatotoxic (per broader literature on peroxisomal C27-bile acid intermediate toxicity — see Ferdinandusse & Houten review) and drive progressive hepatocellular injury, manifesting histologically as hepatic fibrosis with hepatocellular regeneration [demonstrated by liver biopsy in the index patient].
7. Progressive hepatocyte injury and fibrosis result in worsening hepatosplenomegaly, impaired hepatic synthetic function (coagulopathy), and secondary hematologic complications (iron-deficiency anemia, evolving to pancytopenia, likely reflecting combined nutritional deficiency and hypersplenism) [clinical course as reported].
8. Progressive fibrosis culminates in cirrhosis-associated portal hypertension and decompensated liver failure, ultimately requiring liver transplantation (performed at age 4 years in the index case) [clinical outcome reported].

Where the chain is inferred rather than directly demonstrated for this specific human patient: the causal link from "bile acid deficiency" to "fat/vitamin malabsorption" (step 5) and the precise mechanism of C27-intermediate hepatotoxicity (step 6) are extrapolated from general bile acid synthesis defect pathophysiology and from separate toxicological literature on C27 bile acid intermediates [PMID reference: "Toxicity of peroxisomal C27-bile acid intermediates," ScienceDirect/Mol Genet Metab], not established by mechanistic study within the single CBAS5 patient.

Molecular pathways

• Alternative (acidic) bile acid synthesis pathway: cholesterol → (CYP27A1, mitochondrial) → 3α,7α,12α-trihydroxycholestanoic acid (THCA) / 3α,7α-dihydroxycholestanoic acid (DHCA) → [ABCD3-mediated peroxisomal import — the blocked step] → peroxisomal β-oxidation (AMACR, ACOX2, HSD17B4, SCPx/thiolase) → cholyl-CoA / chenodeoxycholyl-CoA → conjugation (BAAT) → taurine/glycine-conjugated CA/CDCA.
• Suggested GO terms: GO:0006699 (bile acid biosynthetic process); GO:0007031 (peroxisome organization, contextual); GO:1990542 (mitochondrial transmembrane transport, contextual to CYP27A1 step); GO:0043433 (negative regulation of DNA-binding transcription factor activity — not relevant, omit); more precisely GO:0006699 and a peroxisomal transmembrane transport term (e.g., GO:1990542-adjacent peroxisomal fatty-acyl-CoA transport — check exact GO ID during curation, e.g. GO:0015916 fatty-acyl-CoA transport).

Cellular processes

• Peroxisomal β-oxidation dysfunction (GO:0006635, fatty acid β-oxidation).
• Secondary hepatocellular injury/fibrogenesis (activation of hepatic stellate cells — consistent with the KB's fibrotic_response mechanism module as a conformance target once curated).

Protein dysfunction

ABCD3 loss of function via C-terminal truncation removing part of the nucleotide-binding domain — predicted to abolish ATP-binding/hydrolysis-coupled substrate translocation (structural inference from ABC-transporter biology; direct biophysical characterization of this specific truncated protein was not reported, though recent cryo-EM/structural work on wild-type ABCD3 substrate transport mechanism is now available — PMID:40501884, PNAS 2025 — and could inform future structure-function interpretation of pathogenic variants).

Metabolic changes

Bile acid pool composition shift: reduced mature C24 bile acids (CA, CDCA), elevated unconjugated bile acids, marked accumulation of C26/C27 bile acid intermediates DHCA and THCA in plasma and (per mouse model) liver, bile, and intestine.

Tissue damage mechanisms

Cholestatic/toxic hepatocellular injury progressing to fibrosis and cirrhosis, analogous to the mechanism proposed for other C27-bile-acid-intermediate-accumulating disorders (bile acid intermediate toxicity, oxidative stress in hepatocytes — inferred, not directly assayed in the human case).

Biochemical abnormalities

Peroxisomal transporter (ABC transporter) deficiency — a transport defect rather than an enzymatic deficiency, distinguishing CBAS5 mechanistically from CBAS1 (HSD3B7), CBAS2 (AKR1D1), CBAS3 (CYP7B1), and CBAS4 (AMACR), all of which are catalytic enzyme defects.

Molecular profiling / advanced technologies

No transcriptomic, proteomic, metabolomic (beyond targeted bile acid mass spectrometry), single-cell, or spatial data specific to the human CBAS5 patient have been published. The Abcd3−/− mouse has been studied with targeted and untargeted metabolomics, histology, immunoblotting, and stable isotope tracing (Ranea-Robles et al., J Inherit Metab Dis 2021, PMID pending verification — reported via bioRxiv/JIMD), revealing broader roles for ABCD3 in dicarboxylic fatty acid metabolism, hepatic lipid homeostasis, lipodystrophy, increased circulating free fatty acids, decreased ketone bodies, enhanced hepatic cholesterol synthesis, and decreased hepatic de novo lipogenesis — phenotypes beyond the bile acid axis alone.

Suggested CL/UBERON/GO term bindings: hepatocyte (CL:0000182); peroxisome (GO:0005777, cellular component); liver (UBERON:0002107); bile canaliculus (UBERON:0001281, if bile secretion specifically implicated).

7. Anatomical Structures Affected

Organ level: - Primary: Liver (hepatocellular injury, fibrosis, cirrhosis) — UBERON:0002107. - Secondary: Spleen (splenomegaly, likely secondary to portal hypertension/hypersplenism) — UBERON:0002106; hematopoietic system (anemia, pancytopenia) secondary to hypersplenism and/or nutritional deficiency; coagulation system (coagulopathy from impaired hepatic synthetic function and vitamin K malabsorption). - Body systems: Hepatobiliary system primarily; hematologic system secondarily; (gastrointestinal system inferred, via fat/fat-soluble vitamin malabsorption, though not explicitly detailed in the single case report).

Tissue/cell level: Hepatocytes are the principal affected cell type (site of bile acid synthesis and of ABCD3 expression/peroxisomal metabolism). Cell Ontology term: hepatocyte (CL:0000182). Hepatic stellate cells are plausibly involved in the fibrotic response (CL:0000632), by analogy with the KB's general fibrotic_response module, though not specifically documented for this entry.

Subcellular level: Peroxisome (GO:0005777) is the defining subcellular compartment — ABCD3 is a peroxisomal membrane protein (GO:0005778, peroxisomal membrane), and the defect is specifically one of peroxisomal matrix protein/substrate import.

Localization: Diffuse hepatic involvement (not focal/lateralized); no laterality applicable.

8. Temporal Development

Onset: The single reported patient presented clinically at 1.5 years of age with hepatosplenomegaly, anemia, and coagulopathy — later than the neonatal-onset cholestasis typical of CBAS1/CBAS2, though the molecular defect is congenital from birth. Onset pattern: insidious/subacute, discovered on evaluation of hepatosplenomegaly rather than at birth.

Progression: Progressive — hepatic fibrosis at biopsy evolved over time to pancytopenia, bleeding, and portal hypertension, ultimately requiring liver transplantation at age 4 years (roughly 2.5 years after presentation). Disease course pattern: chronic, progressive, non-remitting in the absence of effective disease-modifying therapy in this case.

Patterns: No remission was reported (spontaneous or treatment-induced) in the index case; the patient proceeded to transplantation, and — per available search summaries — died shortly thereafter (this specific outcome detail should be verified against the primary paper's full text before being asserted as a fact in the KB, since it was derived from a secondary summary rather than a directly quoted primary-source sentence).

Critical periods: Not established; given the fatal course in the only reported case, no data exist on whether earlier biochemical diagnosis (e.g., via newborn or targeted bile acid screening) and earlier bile acid replacement therapy would alter the natural history — this is an open question analogous to the demonstrated benefit of early cholic acid therapy in CBAS1/CBAS2.

9. Inheritance and Population

Epidemiology: CBAS5 is exceptionally rare — a single published family/patient as of the most recent literature identified in this search. No prevalence or incidence estimate can be computed; it should be curated as prevalence_class: NOT_YET_DOCUMENTED with measure_type: CASES_IN_LITERATURE (n=1).

Inheritance pattern: Autosomal recessive — the index patient was homozygous for the causal ABCD3 deletion, born to consanguineous parents, consistent with AR transmission [PMID:25326392].

Penetrance: Presumed complete in the homozygous state based on the single reported case, but with n=1 this cannot be statistically established.

Expressivity: Unknown/not assessable from a single case.

Genetic anticipation: Not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not reported.

Founder effects: Not established — the reported deletion has not been reported as a recurrent founder allele in any specific population; the consanguineous Turkish family context suggests a private/family-specific allele rather than a population founder variant, though this has not been formally tested against population databases such as gnomAD in this session.

Consanguinity: Present and central to the single reported case (consanguineous Turkish parents), consistent with the ultra-rare, presumably private nature of the causal allele.

Carrier frequency: Unknown; not calculable from gnomAD/population databases within available search results for this specific variant (would need direct gnomAD/ClinVar lookup for the ABCD3 c.della region during KB curation).

Population demographics: The only reported family is of Turkish ethnicity; no broader ethnic or geographic distribution data exist. Sex ratio and age distribution cannot be estimated from a single female case.

10. Diagnostics

Clinical/laboratory tests: - Plasma bile acid profiling by LC-MS/MS: the diagnostic cornerstone — shows markedly elevated C27 bile acid intermediates (DHCA, THCA) with reduced mature C24 primary bile acids and increased unconjugated bile acid fraction. This is the same biochemical modality (LC-ESI-MS-MS) used across the CBAS1–5 spectrum and proposed for expanded newborn screening panels. - Urinary bile acid analysis: shows low fraction of primary bile acids and abnormal/atypical bile acid species (as generally described for CBAS spectrum disorders; specific urinary profile for CBAS5 not separately detailed in available sources). - Liver biochemistry: elevated transaminases; synthetic dysfunction (coagulopathy) in advanced disease. - Liver biopsy/histopathology: fibrosis with hepatocellular regeneration in the index case; SNOMED CT/pathology term for hepatic fibrosis applicable. - Very-long-chain fatty acids (VLCFA) and phytanic/pristanic acid: plausible adjunct given ABCD3's broader peroxisomal substrate range (branched-chain and dicarboxylic fatty acids), though not specifically emphasized as diagnostic in the human case (this is inferred from ABCD3 biology and mouse model findings, not confirmed as a clinical diagnostic test performed in the patient).

Genetic testing: - Single-gene ABCD3 sequencing or targeted bile acid synthesis defect gene panel (alongside HSD3B7, AKR1D1, CYP7B1, AMACR) is the recommended approach once biochemical bile acid profiling suggests a peroxisomal/alternative-pathway defect. - Whole-exome/genome sequencing is appropriate given the extreme rarity and lack of a "typical" mutational hotspot (the one reported variant is a large deletion, which WES with appropriate CNV-calling, or WGS, would be needed to reliably detect — a caveat for diagnostic yield). - GTR lists a clinical test for "Bile acid synthesis defect, congenital, 5" (ABCD3 gene, full coding exon sequence analysis, postnatal).

Differential diagnosis: Other CBAS entries (CBAS1–4), progressive familial intrahepatic cholestasis (PFIC1–6/ABCB4, ABCB11, ATP8B1), Zellweger spectrum peroxisome biogenesis disorders (given ABCD3's peroxisomal localization and the phenotypic overlap of neonatal liver disease), biliary atresia, and other neonatal/infantile cholestasis etiologies.

Screening: Not currently part of standard newborn screening; the broader CBAS literature (e.g., recent AKR1D1 newborn-screening discussion, PMID:41387259) argues for adding bile acid mass spectrometry to expanded newborn panels, which would in principle also detect CBAS5, though this has not been specifically validated for ABCD3 deficiency.

11. Outcome/Prognosis

Survival/mortality: With a single reported case, no survival statistics can be generated. The index patient's disease progressed to liver failure requiring transplantation at age 4; available secondary sources indicate a fatal outcome shortly post-transplant, though this specific claim requires verification against the primary paper's full text before being asserted with a PMID citation in the KB (flagging per the attribution discipline that a summarized/derived claim is a lead, not a verified quote).

Morbidity: Severe — progressive hepatic fibrosis/cirrhosis, portal hypertension, coagulopathy, hematologic compromise (anemia progressing to pancytopenia).

Complications: Hepatosplenomegaly → fibrosis → cirrhosis → portal hypertension → bleeding/coagulopathy → liver failure → transplantation, with post-transplant mortality reported in the single case.

Recovery potential: Unknown whether earlier diagnosis and bile acid replacement therapy (as is effective in CBAS1/CBAS2) would alter the trajectory — no such intervention was reported as attempted/effective in the single published CBAS5 case, unlike the well-documented efficacy of cholic acid therapy in HSD3B7 and AKR1D1 deficiency.

Prognostic factors: Given n=1, no formal prognostic factor analysis exists. By analogy with other bile acid synthesis defects, earlier diagnosis/earlier bile acid replacement is plausibly prognostic, but unproven for CBAS5 specifically.

12. Treatment

Pharmacotherapy — bile acid replacement: Oral cholic acid therapy is the established, evidence-based treatment for most congenital bile acid synthesis defects, including CBAS1 (HSD3B7) and CBAS2 (AKR1D1), where it is highly effective (e.g., a case series of 16 AKR1D1-deficient patients treated with cholic acid showing favorable outcomes, PMC10704681; systematic review of cholic acid effectiveness/safety across bile acid synthesis defects, Orphanet J Rare Dis 2024). However, whether cholic acid replacement is similarly effective in CBAS5 is not established from available sources — CBAS5 is mechanistically a transport defect occurring after the mitochondrial CYP27A1 step but before peroxisomal chain-shortening, so exogenous cholic acid (which provides negative feedback on CYP7A1 via FXR-mediated suppression, reducing production of toxic upstream intermediates) is mechanistically plausible as a therapeutic strategy by the same rationale as for other CBAS entries, but this has not been specifically documented as attempted/successful in the single reported CBAS5 patient in the sources retrieved. - Suggested NCIT term: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bound to cholic acid (CHEBI:29103, cholic acid) if/when curated with supporting citation.

Surgical/interventional: Liver transplantation — performed in the index patient at age 4 years for decompensated liver failure/portal hypertension; NCIT term NCIT:C15289 (Organ Transplantation).

Supportive care: Management of coagulopathy (likely including vitamin K supplementation given fat-soluble vitamin malabsorption risk — inferred, not explicitly reported), nutritional support, and management of portal hypertension complications would be standard supportive measures for progressive cholestatic liver disease, though not itemized in the single case report retrieved.

Experimental/investigational: No CBAS5-specific clinical trials identified (ClinicalTrials.gov searches for bile acid synthesis defects, e.g., NCT01589523 "GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis," are relevant to the broader CBAS disease class but not confirmed to include or exclude ABCD3-specific enrollment).

Treatment outcomes: Cannot be assessed for CBAS5 specifically due to lack of reported treatment trial in the single case (the patient proceeded directly to transplantation rather than being reported as treated with bile acid replacement first, per available sources — this should be verified against full text).

13. Prevention

Primary prevention: Not applicable beyond genetic counseling in consanguineous families with a known familial ABCD3 variant.

Secondary prevention: Early biochemical (bile acid mass spectrometry) or genetic diagnosis in at-risk families (i.e., relatives of the index family, or future consanguineous unions in populations where the variant might recur) could in principle allow earlier initiation of bile acid replacement therapy before irreversible fibrosis develops, by direct analogy with the demonstrated benefit of early treatment in CBAS1/CBAS2 — though this specific preventive strategy has not been validated in CBAS5.

Genetic counseling: Recommended for the reported consanguineous family given autosomal recessive inheritance and 25% recurrence risk for future pregnancies; prenatal or preimplantation genetic testing would be feasible once the familial variant is known. NCIT term: NCIT:C15240 (Genetic Counseling).

Carrier/prenatal screening: Not standardized given the extreme rarity and single-family basis of the disease; would only be relevant within the specific reported family or its extended relatives.

14. Other Species / Natural Disease

No naturally occurring CBAS5/ABCD3-deficiency disease has been reported in non-human species (no OMIA entry identified). ABCD3 is broadly conserved across mammals (human protein 95% identical to rat), but no spontaneous veterinary case has been published.

15. Model Organisms

Mouse (Mus musculus, NCBITaxon:10090): The primary and only well-characterized animal model. - Original Abcd3−/− knockout (Ferdinandusse et al., 2015, PMID:25326392): confirmed reduction of C24 bile acids with significant accumulation of C27-bile acid intermediates in liver, bile, and intestine, directly recapitulating the human biochemical phenotype and validating ABCD3's role in bile acid chain-shortening. Pronounced hepatomegaly was also observed, without histological steatosis, similar to the human phenotype pattern. - CRISPR-Cas9-generated Abcd3 KO mouse (Ranea-Robles et al., J Inherit Metab Dis 2021, referenced via bioRxiv preprint and PNAS-adjacent structural work): extended the phenotype characterization to broader lipid metabolism — lipodystrophy, elevated circulating free fatty acids, decreased ketone bodies, enhanced hepatic cholesterol synthesis, decreased hepatic de novo lipogenesis, and a major role for ABCD3 in dicarboxylic fatty acid metabolism — indicating the mouse model captures both the bile acid axis and additional peroxisomal fatty acid metabolic roles of ABCD3 not emphasized in the single human case. - Fidelity/limitations: The mouse model faithfully recapitulates the core biochemical signature (C24 bile acid deficiency, C27 intermediate accumulation) but the reported mouse phenotype emphasizes hepatomegaly and systemic lipid/metabolic dysregulation rather than the progressive fibrosis-to-cirrhosis trajectory documented in the single human patient — it is unclear from available sources whether the mouse model recapitulates progressive hepatic fibrosis/cirrhosis or is more useful as a biochemical/metabolic model. This would need direct review of the primary mouse-phenotyping papers to assess fidelity and relationship (RECAPITULATES vs PARTIALLY_RECAPITULATES) for KB curation.

In vitro models: Patient-derived skin fibroblasts were used in the founding study to functionally confirm the ABCD3 protein defect (immunoblot loss of protein) — this constitutes IN_VITRO evidence supporting the causal genotype-phenotype link.

Summary of Key Citation-Ready Sources

Curation caveat (important for KB use): Nearly every clinical claim above traces to a single published family described in one primary paper (PMID:25326392), supplemented by mouse-model and structural-biology literature that establishes ABCD3's general biochemical role but does not independently validate the human clinical course. Several specific clinical details in this report (particularly the reported post-transplant mortality and the absence of attempted cholic acid therapy) were derived from secondary search-engine summaries of the primary paper rather than a direct, verified quote from the paper's own text, and should be re-verified against the primary source's exact wording (via just fetch-reference PMID:25326392 and exact-snippet extraction) before being asserted as sourced fact in any evidence: block — per this repository's evidence discipline, a paraphrase is a lead, not a citation.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:25326392 (abstract only): "only one family has been described in the literature and phenotypic association is not confirmed"
• Text part not found as substring: 'only one family has been described in the literature and phenotypic association is not confirmed' (note: only abstract available for PMID:25326392, full text may contain this excerpt)

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0031994 (1 mention) - the report calls it "Abnormal bile acid level"; HP calls it Bronchial breath sound

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0043433 (obsolete negative regulation of DNA-binding transcription factor activity) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0001928 (1 mention) - the report calls it "Abnormal coagulation"; HP calls it Abnormality of coagulation
• HP:0031964 (1 mention) - the report calls it "Elevated hepatic transaminase"; HP calls it Elevated circulating alanine aminotransferase concentration, and lists "Elevated serum glutamic-pyruvic transaminase" among its other names